Verrica Pharmaceuticals Analyst Price Targets - Benzinga

Verrica Pharmaceuticals Inc

VRCANASDAQ

Trade with Public

Trade with Public

$5.26

-0.0427-0.81%

Last update: Sep 8, 8:39 AM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Verrica Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Verrica Pharmaceuticals (VRCA).

Price Target Range — 7 Quarters

Analyst Consensus — 6 Analysts

4Buy

2Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$10Upside to Avg. PT+87.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 26, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Assumes	Buy	$12
Dec 18, 2025	Brookline Capital	Kemp Dolliver	Upgrade	Hold→Buy	$17
May 14, 2025	Needham	Serge Belanger	Maintained	Hold	—
Apr 9, 2025	Needham	Serge Belanger	Maintained	Hold	—
Apr 8, 2025	HC Wainwright & Co.	Oren Livnat	Maintained	Neutral	—
Mar 12, 2025	Needham	Serge Belanger	Maintained	Hold	—
Dec 20, 2024	Needham	Serge Belanger	Maintained	Hold	—
Nov 6, 2024	HC Wainwright & Co.	Oren Livnat	Downgrade	Buy→Neutral	—
Nov 5, 2024	Needham	Serge Belanger	Maintained	Hold	—
Nov 5, 2024	RBC Capital	Gregory Renza	Downgrade	Outperform→Sector Perform	$11→$2
Oct 21, 2024	TD Cowen	Stacy Ku	PT Cut	Buy	$15→$10
Oct 4, 2024	RBC Capital	Gregory Renza	PT Cut	Outperform	$13→$11
Oct 3, 2024	Needham	Serge Belanger	Downgrade	Buy→Hold	$12
Oct 2, 2024	Brookline Capital	Kemp Dolliver	Downgrade	Buy→Hold	—
Aug 15, 2024	RBC Capital	Gregory Renza	PT Cut	Outperform	$14→$13
Aug 15, 2024	Needham	Serge Belanger	PT Cut	Buy	$16→$12
May 16, 2024	Needham	Serge Belanger	Maintained	Buy	$16
May 14, 2024	HC Wainwright & Co.	Oren Livnat	PT Raise	Buy	$13→$14
May 14, 2024	Needham	Serge Belanger	PT Raise	Buy	$8→$16
Apr 10, 2024	Needham	—	Maintained	Buy	$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Brookline Capital Upgrades Verrica Pharmaceuticals to Buy, Announces $17 Price Target

Brookline Capital analyst Kemp Dolliver upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Buy and announces $17 price target.

Benzinga Newsdesk

PRO
Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Hold.

Benzinga Newsdesk

PRO
Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Verrica Pharmaceuticalsto Neutral

HC Wainwright & Co. analyst Oren Livnat reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) from Neutral to Neutral.

Benzinga Newsdesk

PRO
Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Hold.

Benzinga Newsdesk